Mycophenolate mofetil: long-term outcomes in solid organ transplantation

References

• Takemoto SK. Patterns and outcomes for maintenance immunosuppression in the UNOS Renal Transplant Registry. Am. J. Transplant.2(Suppl. 3), A42 (2002).
   Google Scholar
• Immunosuppression: 1993–2003 OPTN/SRTR Annual Report (2006).
   Google Scholar
• Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami T, Dyke DB. Immunosuppression: practice and trends. Am. J. Transplant.4(Suppl. 9), 38–53 (2004).
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil (RS-61443): mechanisms of action and effects in transplantation. Transplant. Reviews7, 129–139 (1993).
   Google Scholar
• Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet2(7786), 1067–1069 (1972).
   PubMed Web of Science ®Google Scholar
• Allison AC, Hovi T, Watts RW, Webster AD. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet2(7946), 1179–1183 (1975).
   PubMed Web of Science ®Google Scholar
• Allison AC, Hovi T, Watts RW, Webster AD. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp.48, 207–224 (1977).
   Google Scholar
• Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J.113(3), 515–524 (1969).
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin. Transplant.10(1 Pt 2), 77–84 (1996).
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology47(2–3), 85–118 (2000).
   PubMed Web of Science ®Google Scholar
• Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology47(2–3), 215–245 (2000).
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation80(2 Suppl.), S181–S190 (2005).
   PubMed Web of Science ®Google Scholar
• Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand. J. Immunol.33(2), 161–173 (1991).
   PubMed Web of Science ®Google Scholar
• Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant. Proc.25(3 Suppl. 2), 67–70 (1993).
   PubMed Web of Science ®Google Scholar
• Haug C, Schmid-Kotsas A, Linder T et al. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin. Sci. (Lond.)103(Suppl. 48), 76S–80S (2002).
   PubMedGoogle Scholar
• Wilasrusmee C, Da Silva M, Singh B et al. Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction. Clin. Transplant.17(Suppl. 9), 6–12 (2003).
   PubMed Web of Science ®Google Scholar
• Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation62(9), 1363–1366 (1996).
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J. Am. Soc. Nephrol.10(7), 1542–1549 (1999).
   PubMed Web of Science ®Google Scholar
• Senda M, DeLustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation60(10), 1143–1148 (1995).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Iturbe B, Quiroz Y, Nava M et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am. J. Physiol. Renal Physiol.282(2), F191–F201 (2002).
   PubMed Web of Science ®Google Scholar
• Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant. Proc.22(4), 1659–1662 (1990).
   PubMed Web of Science ®Google Scholar
• Morris RE, Wang J, Blum JR et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant. Proc.23(2 Suppl. 2), 19–25 (1991).
   PubMed Web of Science ®Google Scholar
• Hao L, Lafferty KJ, Allison AC, Eugui EM. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant. Proc.22(2), 876–879 (1990).
   PubMed Web of Science ®Google Scholar
• Sollinger HW. A few memories from the beginning. Transplantation80(2 Suppl.), S178–S180 (2005).
   Google Scholar
• Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol.36(4), 315–324 (1996).
   PubMed Web of Science ®Google Scholar
• Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443), a short review. Transplant. Proc.28(2), 925–929 (1996).
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am. J. Transplant.3(5), 534–542 (2003).
   PubMed Web of Science ®Google Scholar
• Shipkova M, Wieland E, Schutz E et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant. Proc.33(1–2), 1080–1081 (2001).
   PubMed Web of Science ®Google Scholar
• Shipkova M, Strassburg CP, Braun F et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br. J. Pharmacol.132(5), 1027–1034 (2001).
   PubMed Web of Science ®Google Scholar
• Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit.25(1), 1–16 (2003).
   PubMed Web of Science ®Google Scholar
• Weber LT, Shipkova M, Lamersdorf T et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J. Am. Soc. Nephrol.9(8), 1511–1520 (1998).
   PubMed Web of Science ®Google Scholar
• Kaplan B, Meier-Kriesche HU, Friedman G et al. The effect of renal insufficiency on mycophenolic acid protein binding. J. Clin. Pharmacol.39(7), 715–720 (1999).
   PubMed Web of Science ®Google Scholar
• Bullingham R, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet.34, 429–455 (1998).
   PubMed Web of Science ®Google Scholar
• Weber LT, Lamersdorf T, Shipkova M et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther. Drug Monit.21(5), 498–506 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson HJ, Swan SK, Heim-Duthoy KL, Nicholls AJ, Tsina I, Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin. Pharmacol. Ther.63(5), 512–518 (1998).
   PubMed Web of Science ®Google Scholar
• Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation65(8), 1127–1129 (1998).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther. Drug Monit.22(1), 27–30 (2000).
   PubMed Web of Science ®Google Scholar
• Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin. Chem.41(7), 1011–1017 (1995).
   PubMed Web of Science ®Google Scholar
• Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther. Drug Monit.21(1), 35–43 (1999).
   PubMed Web of Science ®Google Scholar
• Morii M, Ueno K, Ogawa A et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin. Pharmacol. Ther.68(6), 613–616 (2000).
   PubMed Web of Science ®Google Scholar
• van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug Monit.23(2), 119–128 (2001).
   PubMed Web of Science ®Google Scholar
• Shipkova M, Armstrong VW, Kuypers D et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther. Drug Monit.23(6), 717–721 (2001).
   PubMed Web of Science ®Google Scholar
• Smak Gregoor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol. Dial. Transplant.14(3), 706–708 (1999).
   PubMed Web of Science ®Google Scholar
• Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl. Immunol.5(3), 225–232 (1997).
   PubMed Web of Science ®Google Scholar
• Zucker K, Rosen A, Tsaroucha A et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. Transplant. Proc.29(1–2), 334–336 (1997).
   PubMed Web of Science ®Google Scholar
• Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation74(8), 1070–1076 (2002).
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int.62(3), 1060–1067 (2002).
   PubMed Web of Science ®Google Scholar
• Langman LJ, Shapiro AM, Lakey JR, LeGatt DF, Kneteman NM, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. Transplantation61(1), 87–92 (1996).
   PubMed Web of Science ®Google Scholar
• Millan O, Oppenheimer F, Brunet M et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin. Chem.46(9), 1376–1383 (2000).
   PubMed Web of Science ®Google Scholar
• Glander P, Hambach P, Braun KP et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant.4(12), 2045–2051 (2004).
   PubMed Web of Science ®Google Scholar
• Danovitch GM. Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials. Kidney Int. Suppl.52, S93–S96 (1995).
   Google Scholar
• Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation63(1), 39–47 (1997).
   PubMed Web of Science ®Google Scholar
• Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443 – a phase I clinical trial and pilot rescue study. Transplantation53(2), 428–432 (1992).
   PubMed Web of Science ®Google Scholar
• Deierhoi MH, Kauffman RS, Hudson SL et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann. Surg.217(5), 476–482 (1993).
   PubMed Web of Science ®Google Scholar
• Deierhoi MH, Sollinger HW, Diethelm AG, Belzer FO, Kauffman RS. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant. Proc.25(1 Pt 1), 693–694 (1993).
   PubMed Web of Science ®Google Scholar
• Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation57(6), 857–859 (1994).
   PubMed Web of Science ®Google Scholar
• Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation60(3), 225–232 (1995).
   PubMed Web of Science ®Google Scholar
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet345(8961), 1321–1325 (1995).
   PubMed Web of Science ®Google Scholar
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation61(7), 1029–1037 (1996).
   PubMed Web of Science ®Google Scholar
• Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African–American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation64(9), 1277–1282 (1997).
   PubMed Web of Science ®Google Scholar
• Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation68(3), 391–396 (1999).
   PubMed Web of Science ®Google Scholar
• Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation80(2 Suppl.), S254–S264 (2005).
   PubMed Web of Science ®Google Scholar
• Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int.51(5), 1583–1589 (1997).
   PubMed Web of Science ®Google Scholar
• Weir MR, Anderson L, Fink JC et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation64(12), 1706–1710 (1997).
   PubMed Web of Science ®Google Scholar
• Dickinson DM, Bryant PC, Williams MC et al. Transplant data: sources, collection, and caveats. Am. J. Transplant.4(Suppl. 9), 13–26 (2004).
   PubMedGoogle Scholar
• Merion RM. 2004 SRTR Report on the State of Transplantation. Am. J. Transplant.5(4 Pt 2), 841–842 (2005).
   Web of Science ®Google Scholar
• Meier-Kriesche H, Ojo AO, Arndorfer JA et al. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Transplant. Proc.33(1–2), 1005–1006 (2001).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Ojo AO, Leichtman AB et al. Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients. J. Am. Soc. Nephrol.11(12), 2366–2370 (2000).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Ojo AO, Leichtman AB et al. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation71(3), 398–401 (2001).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am. J. Transplant.3(1), 68–73 (2003).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation75(8), 1341–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation69(11), 2405–2409 (2000).
   PubMed Web of Science ®Google Scholar
• Kaplan B, Schold J, Meier-Kriesche HU. Overview of large database analysis in renal transplantation. Am. J. Transplant.3(9), 1052–1056 (2003).
   PubMed Web of Science ®Google Scholar
• Hill AB. Statistical evidence and inference. In: Principles of Medical Statistics. Hill AB (Ed.), The Lancet Limited, London, UK, 309–323 (1971).
   Google Scholar
• Opelz G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation40(3), 240–243 (1985).
   PubMed Web of Science ®Google Scholar
• Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation69(5), 834–841 (2000).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Steffen BJ, Chu AH et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am. J. Transplant.4(12), 2058–2066 (2004).
   PubMed Web of Science ®Google Scholar
• Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet356(9225), 194–202 (2000).
   PubMed Web of Science ®Google Scholar
• MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation71(2), 271–280 (2001).
   PubMed Web of Science ®Google Scholar
• Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation62(3), 311–316 (1996).
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation77(2), 252–258 (2004).
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation77(2), 244–251 (2004).
   PubMed Web of Science ®Google Scholar
• Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet356(9225), 194–202 (2000).
   PubMed Web of Science ®Google Scholar
• MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation71(2), 271–280 (2001).
   PubMed Web of Science ®Google Scholar
• Formica RN Jr, Lorber KM, Friedman AL et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. Transplant. Proc.35(3 Suppl.), 95S–98S (2003).
   Google Scholar
• MacDonald A. Improving tolerability of immunosuppressive regimens. Transplantation72(12 Suppl.), S105–S112 (2001).
   Google Scholar
• MacDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant. Proc.35(3 Suppl.), 201S–208S (2003).
   Google Scholar
• Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation; Results at one year. Transplantation80(3), 303–309 (2005).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR, Howard R, Fujita S, Kaplan B. Rapamycin in combination with Tacrolimus is associated with worse renal allograft survival compared to Mycophenolate Mofetil combined with Tacrolimus. Am. J. Transplant. (2005) (In Press).
   Google Scholar
• Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am. J. Transplant.4(11), 1776–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am. J. Transplant.6(3), 514–522 (2006).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Hricik DE. Are we ready to give up on calcineurin inhibitors? Am. J. Transplant.6(3), 445–446 (2006).
   PubMed Web of Science ®Google Scholar
• Halloran PF, Langone AJ, Helderman JH, Kaplan B. Assessing long-term nephron loss: is it time to kick the CAN grading system? Am. J. Transplant.4(11), 1729–1730 (2004).
   PubMed Web of Science ®Google Scholar
• Danovitch GM. Immunosuppressive medications and protocols. In: Handbook of Kidney Tranapslantation. Danovitch GM (Ed.), Lippincott Williams and Wilkins, PA, USA, 72–134 (2005).
   Google Scholar
• Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin. Transplant.17(3), 234–241 (2003).
   PubMed Web of Science ®Google Scholar
• Humar A, Parr E, Drangstveit MB, Kandaswamy R, Gruessner AC, Sutherland DE. Steroid withdrawal in pancreas transplant recipients. Clin. Transplant.14(1), 75–78 (2000).
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J. Am. Soc. Nephrol.11(10), 1910–1917 (2000).
   PubMed Web of Science ®Google Scholar
• Matas AJ, Kandaswamy R, Humar A et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann. Surg.240(3), 510–516 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar MS, Xiao SG, Fyfe B et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin. Transplant.19(1), 61–69 (2005).
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Leventhal JR, Koffron AJ et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation73(2), 169–177 (2002).
   PubMed Web of Science ®Google Scholar
• Paul LC. Chronic allograft nephropathy: an update. Kidney Int.56(3), 783–793 (1999).
   PubMed Web of Science ®Google Scholar
• Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol.12(3), 574–582 (2001).
   PubMed Web of Science ®Google Scholar
• Terasaki PI. Humoral theory of transplantation. Am. J. Transplant.3(6), 665–673 (2003).
   PubMed Web of Science ®Google Scholar
• Mihatsch MJ, Morozumi K, Strom EH, Ryffel B, Gudat F, Thiel G. Renal transplant morphology after long-term therapy with cyclosporine. Transplant. Proc.27(1), 39–42 (1995).
   PubMed Web of Science ®Google Scholar
• Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int.59(4), 1567–1573 (2001).
   PubMed Web of Science ®Google Scholar
• Dudley C, Pohanka E, Riad H et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the “creeping creatinine” study. Transplantation79(4), 466–475 (2005).
   PubMed Web of Science ®Google Scholar
• Theruvath TP, Saidman SL, Mauiyyedi S et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation72(1), 77–83 (2001).
   PubMed Web of Science ®Google Scholar
• David KM, Morris JA, Steffen BJ, Chi-Burris KS, Gotz VP, Gordon RD. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin. Transplant.19(2), 279–285 (2005).
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int.62(3), 1060–1067 (2002).
   PubMed Web of Science ®Google Scholar
• Rischen-Vos J, van der Woude FJ, Tegzess AM et al. Increased morbidity and mortality in patients with diabetes mellitus after kidney transplantation as compared with non-diabetic patients. Nephrol. Dial. Transplant.7(5), 433–437 (1992).
   PubMed Web of Science ®Google Scholar
• Kumar S, Merchant MR, Dyer P et al. Increased mortality due to cardiovascular disease in type 1 diabetic patients transplanted for end-stage renal failure. Diabet. Med.11(10), 987–991 (1994).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation75(8), 1291–1295 (2003).
   PubMed Web of Science ®Google Scholar
• Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am. J. Transplant.5(12), 2954–2960 (2005).
   PubMed Web of Science ®Google Scholar
• Funch DP, Ko HH, Travasso J et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation80(9), 1174–1180 (2005).
   PubMed Web of Science ®Google Scholar
• Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr. Opin. Nephrol. Hypertens.11(6), 609–618 (2002).
   PubMed Web of Science ®Google Scholar
• Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J. Am. Soc. Nephrol.13(3), 779–787 (2002).
   PubMed Web of Science ®Google Scholar
• Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation71(5), 652–658 (2001).
   PubMed Web of Science ®Google Scholar
• Pascual M, Saidman S, Tolkoff-Rubin N et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation66(11), 1460–1464 (1998).
   PubMed Web of Science ®Google Scholar
• Theruvath TP, Saidman SL, Mauiyyedi S et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation72(1), 77–83 (2001).
   PubMed Web of Science ®Google Scholar
• Katznelson S, Takemoto SK, Cecka JM. Histocompatibility testing, crossmatching, and allocation of cadaveric kidney transplants. In: Handbook of Kidney Transplantation. Danovitch GM (Ed.), Lippincott, PA, USA, 39–61 (2001).
   Google Scholar
• Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am. J. Transplant.3(6), 653–664 (2003).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Takahashi K, Sonda K et al. ABO-incompatible living kidney donor transplantation: results and immunological aspects. Transplant. Proc.27(1), 1020–1023 (1995).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Takahashi K, Sonda K et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation65(2), 224–228 (1998).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Tokumoto T, Ishikawa N et al. ABO-incompatible living donor kidney transplantation under tacrolimus immunosuppression. Transplant. Proc.32(7), 1711–1713 (2000).
   PubMed Web of Science ®Google Scholar
• Ishida H, Tanabe K, Furusawa M et al. Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity. Transplantation74(8), 1187–1189 (2002).
   PubMed Web of Science ®Google Scholar
• Sonnenday CJ, Ratner LE, Zachary AA et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant. Proc.34(5), 1614–1616 (2002).
   PubMed Web of Science ®Google Scholar
• Schweitzer EJ, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation70(10), 1531–1536 (2000).
   PubMed Web of Science ®Google Scholar
• Rayhill SC, Sollinger HW. Mycophenolate mofetil: experimental and clinical experience. In: Transplantation. Ginns LC, Cosimi AB, Morris PJ (Eds), Blackwell, MO, USA, 147–166 (1999).
   Google Scholar
• Auchincloss H, Shaffer D. Pancreas Transplantation. In: Transplantation. Ginns LC, Cosimi AB, Morris PJ (Eds), Blackwell, MO, USA, 395–421 (1999).
   Google Scholar
• Stratta RJ. Immunosuppression in pancreas transplantation: progress, problems and perspective. Transpl. Immunol.6(2), 69–77 (1998).
   PubMed Web of Science ®Google Scholar
• Stratta RJ, Gaber AO, Shokouh-Amiri MH et al. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. Ann. Surg.229(5), 701–708 (1999).
   PubMed Web of Science ®Google Scholar
• Sollinger HW, Odorico JS, Knechtle SJ, D'Alessandro AM, Kalayoglu M, Pirsch JD. Experience with 500 simultaneous pancreas-kidney transplants. Ann. Surg.228(3), 284–296 (1998).
   PubMed Web of Science ®Google Scholar
• Odorico JS, Pirsch JD, Knechtle SJ, D’Alessandro AM, Sollinger HW. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation66(12), 1751–1759 (1998).
   PubMed Web of Science ®Google Scholar
• Gruessner RW, Sutherland DE, Drangstveit MB, Wrenshall L, Humar A, Gruessner AC. Mycophenolate mofetil in pancreas transplantation. Transplantation66(3), 318–323 (1998).
   PubMed Web of Science ®Google Scholar
• Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation64(12), 1695–1700 (1997).
   PubMed Web of Science ®Google Scholar
• Gruessner AC, Sutherland DE. Analysis of United States (US) and non-US pancreas transplants reported to the United network for organ sharing (UNOS) and the international pancreas transplant registry (IPTR) as of October 2001. Clin. Transpl.41–72 (2001).
   PubMedGoogle Scholar
• Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443), preclinical, clinical, and three-year experience in heart transplantation. J. Heart Lung Transplant.13(4), 571–582 (1994).
   PubMed Web of Science ®Google Scholar
• Ensley RD, Bristow MR, Olsen SL et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation56(1), 75–82 (1993).
   PubMed Web of Science ®Google Scholar
• Kirklin JK, Bourge RC, Naftel DC et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443), initial clinical experience. J. Heart Lung Transplant.13(3), 444–450 (1994).
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation66(4), 507–515 (1998).
   PubMed Web of Science ®Google Scholar
• Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation72(10), 1662–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Tobis JM, Mentzer RM et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am. J. Transplant.6(5 Pt 1), 993–997 (2006).
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation74(11), 1568–1573 (2002).
   PubMed Web of Science ®Google Scholar
• Baryalei M, Zenker D, Pieske B, Tondo K, Dalichau H, Aleksic I. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant. Proc.35(4), 1539–1542 (2003).
   PubMed Web of Science ®Google Scholar
• Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl.7(5), 442–450 (2001).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Baz MA, Sanders L et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation71(12), 1772–1776 (2001).
   PubMed Web of Science ®Google Scholar
• Nelson DR, Soldevila-Pico C, Reed A et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl.7(12), 1064–1070 (2001).
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl.11(7), 750–759 (2005).
   PubMed Web of Science ®Google Scholar
• Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet357(9256), 587–591 (2001).
   PubMed Web of Science ®Google Scholar
• Zuckermann A, Reichenspurner H, Birsan T et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J. Thorac. Cardiovasc. Surg.125(4), 891–900 (2003).
   PubMed Web of Science ®Google Scholar
• Zuckermann A, Klepetko W, Birsan T et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J. Heart Lung Transplant.18(5), 432–440 (1999).
   PubMed Web of Science ®Google Scholar
• Soccal PM, Gasche Y, Favre H, Spiliopoulos A, Nicod LP. Improvement of drug-induced chronic renal failure in lung transplantation. Transplantation68(1), 164–165 (1999).
   PubMed Web of Science ®Google Scholar
• Kaplan B, Srinivas TR, Meier-Kriesche HU. Factors associated with long-term renal allograft survival. Ther. Drug Monit.24(1), 36–39 (2002).
   PubMed Web of Science ®Google Scholar
• Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther. Drug Monit.22(1), 14–19 (2000).
   PubMed Web of Science ®Google Scholar
• Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther. Drug Monit.25(2), 137–157 (2003).
   PubMed Web of Science ®Google Scholar
• Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther.64(6), 672–683 (1998).
   PubMed Web of Science ®Google Scholar
• van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation68(2), 261–266 (1999).
   PubMed Web of Science ®Google Scholar
• Le Meur Y, Buchler M, Lavaud S et al. Concentration controled versus fixed dose of mmf in kidney transplant recipients: preliminary results of a french multicenter randomized study. (Abstract Presented at the American Transplant Congress 2005). Am. J. Transplant.5, A338 (2005).
   Google Scholar
• van Gelder T, Meur YL, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit.28(2), 145–154 (2006).
   PubMed Web of Science ®Google Scholar
• Weber LT, Shipkova M, Armstrong VW et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin. Chem.48(3), 517–525 (2002).
   PubMed Web of Science ®Google Scholar
• Weber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J. Am. Soc. Nephrol.13(3), 759–768 (2002).
   PubMed Web of Science ®Google Scholar
• Weber LT, Schutz E, Lamersdorf T et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol. Dial. Transplant.14(Suppl 4), 34–35 (1999).
   PubMed Web of Science ®Google Scholar
• Meiser BM, Pfeiffer M, Schmidt D et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J. Heart Lung Transplant.18(2), 143–149 (1999).
   PubMed Web of Science ®Google Scholar
• Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther. Drug Monit.22(2), 169–173 (2000).
   PubMed Web of Science ®Google Scholar
• Willis C, Taylor PJ, Salm P, Tett SE, Pillans PI. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther. Drug Monit.22(5), 549–554 (2000).
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med.343(16), 1156–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med.350(10), 971–980 (2004).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med.353(21), 2219–2228 (2005).
   PubMed Web of Science ®Google Scholar
• Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant.20(12), 2725–2732 (2005).
   PubMed Web of Science ®Google Scholar
• Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation80(2 Suppl.), S265–S271 (2005).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant.4(3), 378–383 (2004).
   PubMed Web of Science ®Google Scholar
• Ramos E, Drachenberg CB, Portocarrero M et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin. Transpl.143–153 (2002).
   PubMedGoogle Scholar
• Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am. J. Transplant.5(3), 582–594 (2005).
   PubMed Web of Science ®Google Scholar
• Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am. J. Transplant.4(12), 2132–2134 (2004).
   PubMed Web of Science ®Google Scholar
• Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant.4(2), 237–243 (2004).
   PubMed Web of Science ®Google Scholar
• Salvadori M. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients. Transplant. Proc.37(2), 909–911 (2005).
   PubMed Web of Science ®Google Scholar
• Budde K, Knoll G, Curtis J et al. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. Transplant. Proc.37(2), 912–915 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan MJ. FK-778 Astellas. Curr. Opin. Investig. Drugs6(5), 526–536 (2005).
   PubMedGoogle Scholar
• Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med.353(8), 770–781 (2005).
   PubMed Web of Science ®Google Scholar